Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Olszanski · SciRah

Researcher profile · Semantic Scholar

A. Olszanski

Share profile

A. Olszanski — researcher profile on SciRah

h-index: 42
Works: 251
Citations: 8,753

Most-cited papers

Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.
John A. Thompson, B. Schneider, J. Brahmer, Amaka E. Achufusi +32 more
2022The Journal of the National Comprehensive Cancer Network515 citations
Semantic Scholar
NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021.
S. Swetter, John A. Thompson, M. Albertini, C. Barker +29 more
2021The Journal of the National Comprehensive Cancer Network270 citations
Semantic Scholar
Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial
D. Hong, B. Van Tine, S. Biswas, C. McAlpine +40 more
2023Nature Medicine186 citations Open access
Semantic Scholar
NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2.2024.
John A Thompson, Bryan J. Schneider, J. Brahmer, M. Zaid +41 more
2024The Journal of the National Comprehensive Cancer Network154 citations
Semantic Scholar
NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024.
S. Swetter, Douglas B. Johnson, Mark R. Albertini, C. Barker +34 more
2024The Journal of the National Comprehensive Cancer Network145 citations
Semantic Scholar
Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors
Albiruni Razak, J. Cleary, V. Moreno, M. Boyer +17 more
2020Journal for ImmunoTherapy of Cancer115 citations Open access
Semantic Scholar
OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors
M. Gutierrez, V. Moreno, K. Heinhuis, A. Olszanski +16 more
2020Clinical Cancer Research70 citations Open access
Semantic Scholar
Pilot study of ONCOS-102 and pembrolizumab: remodeling of the tumor micro-environment and clinical outcomes in anti-PD1-resistant advanced melanoma
A. Shoushtari, A. Olszanski, M. Nyakas, T. Hornyak +5 more
2022Clinical Cancer Research51 citations Open access
Semantic Scholar
Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10+ advanced non-small cell lung cancer
G. Blumenschein, S. Devarakonda, M. Johnson, V. Moreno +23 more
2022Journal for ImmunoTherapy of Cancer48 citations Open access
Semantic Scholar
Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors
S. Waqar, C. Robinson, A. Olszanski, A. Spira +10 more
2022Investigational new drugs43 citations Open access
Semantic Scholar
NCCN Guidelines Insights: Uveal Melanoma, Version 1.2019.
P. Rao, C. Barker, D. Coit, Richard W. Joseph +31 more
2020The Journal of the National Comprehensive Cancer Network41 citations
Semantic Scholar
Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma
D. Rasco, T. Medina, P. Corrie, A. Pavlick +12 more
2023Cancer Chemotherapy and Pharmacology37 citations Open access
Semantic Scholar
Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid Tumors
D. Hong, O. Rixe, V. Chiu, P. Forde +9 more
2021Clinical Cancer Research37 citations Open access
Semantic Scholar
A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer
G. Curigliano, G. Shapiro, R. Kristeleit, A. A. Abdul Razak +15 more
2022British Journal of Cancer35 citations Open access
Semantic Scholar
Feasibility and safety of targeting mitochondria for cancer therapy – preclinical characterization of gamitrinib, a first-in-class, mitochondriaL-targeted small molecule Hsp90 inhibitor
Umar Hayat, G. Elliott, A. Olszanski, D. Altieri
2022Cancer Biology & Therapy34 citations Open access
Semantic Scholar
Molecular profiling of melanoma brain metastases compared to primary cutaneous melanoma and to extracranial metastases
G. In, K. Poorman, M. Saul, S. O'Day +11 more
2020OncoTarget30 citations Open access
Semantic Scholar
A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody–drug conjugate, in patients with advanced or metastatic cancer
C. Kollmannsberger, C. Britten, A. Olszanski, J. Walker +6 more
2021Investigational new drugs28 citations
Semantic Scholar
Addressing Recent Failures in Immuno-Oncology Trials to Guide Novel Immunotherapeutic Treatment Strategies
S. Nakhoda, A. Olszanski
2020Pharmaceutical Medicine17 citations Open access
Semantic Scholar
Adverse events reported by cancer patients following administration of a two-dose mRNA COVID-19 vaccine
R. Shulman, D. Weinberg, E. Ross, K. Ruth +27 more
2022The Journal of the National Comprehensive Cancer Network15 citations Open access
Semantic Scholar
A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies
D. Juric, Daniel Anderson, A. Dowlati, J. Rodon +19 more
2025Cancer Research Communications13 citations Open access
Semantic Scholar
476 First-in-human phase 1/2 study of the first-in-class SUMO-activating enzyme inhibitor TAK-981 in patients with advanced or metastatic solid tumors or relapsed/refractory lymphoma: phase 1 results
A. Dudek, D. Juric, A. Dowlati, U. Vaishampayan +14 more
2021Journal for ImmunoTherapy of Cancer13 citations Open access
Semantic Scholar
A phase Ia/Ib dose-escalation study of intravenously administered SB 11285 alone and in combination with nivolumab in patients with advanced solid tumors.
F. Janku, J. Strauss, R. Karim, A. Olszanski +4 more
202012 citations
Semantic Scholar
Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach
K. Ogasawara, P. LoRusso, A. Olszanski, O. Rixe +4 more
2020Cancer Chemotherapy and Pharmacology12 citations
Semantic Scholar
Annals of Surgical Oncology Practice Guidelines Series: Adjuvant and Neoadjuvant Therapy for Melanoma
J. Farma, A. Olszanski, Jane L. Messina, V. Sondak
2024Annals of Surgical Oncology10 citations Open access
Semantic Scholar
SALVO: Single Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma.
L. Kottschade, G. Pond, A. Olszanski, Y. Zakharia +8 more
2023Clinical Cancer Research10 citations Open access
Semantic Scholar
1029P Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced or metastatic solid tumors: Preliminary safety, PK/PD, and anti-tumor activity in a phase I dose escalation study supporting a recommended dose for expansion (RDE)
A. Olszanski, J. J. Luke, P. Lorusso, G. Falchook +14 more
2023Annals of Oncology9 citations Open access
Semantic Scholar
Tumor Mutational Burden and Somatic Mutation Status to Predict Disease Recurrence in Advanced Melanoma
Meghan Hotz, Eileen A. O’Halloran, M. Hill, Kelly Hayden +7 more
2022Melanoma research9 citations Open access
Semantic Scholar
Abstract CT249: First-in-human study of TAK-500, a novel STING agonist immune stimulating antibody conjugate (ISAC), alone and in combination with pembrolizumab in patients with select advanced solid tumors
J. Diamond, Jason T. Henry, G. Falchook, A. Olszanski +11 more
2022Cancer Research9 citations
Semantic Scholar
Impact of Sun Exposure and Tanning Patterns on Next-Generation Sequencing Mutations in Melanoma.
Kimberly Loo, Iman Soliman, M. Renzetti, Tian-Yu Li +4 more
2020Journal of Surgical Research8 citations
Semantic Scholar
996MO Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced/metastatic solid tumors: Data from phase I dose escalation
J. J. Luke, X. Gao, A. Olszanski, R. Sanborn +14 more
2024Annals of Oncology7 citations Open access
Semantic Scholar
KRT-232, a first-in-class, murine double minute 2 inhibitor (MDM2i), for TP53 wild-type (p53WT) Merkel cell carcinoma (MCC) after anti–PD-1/L1 immunotherapy.
M. Wong, C. Kelly, M. Burgess, K. Lewis +6 more
20207 citations
Semantic Scholar
Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade–resistant melanoma: Final analysis from a phase 1b study
M. Milhem, Y. Zakharia, D. Davar, Elizabeth I. Buchbinder +19 more
2025Cancer6 citations Open access
Semantic Scholar
A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors
D. Juric, M. Barve, U. Vaishampayan, Desamparados Roda +18 more
2024Cancer Medicine6 citations Open access
Semantic Scholar
950 Final analysis: phase 1b study investigating intratumoral injection of toll-like receptor 9 agonist vidutolimod ± pembrolizumab in patients with PD-1 blockade–refractory melanoma
J. Kirkwood, Y. Zakharia, D. Davar, E. Buchbinder +20 more
2021Journal for ImmunoTherapy of Cancer6 citations Open access
Semantic Scholar
A phase 1 dose-escalation study of intravenously (IV) administered TAK-676, a novel STING agonist, alone and in combination with pembrolizumab in patients (pts) with advanced or metastatic solid tumors.
G. Falchook, J. Luke, J. Strauss, Xin Gao +11 more
20216 citations
Semantic Scholar
Abstract CT032: CMP-001 demonstrates improved response in noninflamed anti-PD-1 refractory melanoma and response is associated with serum CXCL10
J. Luke, R. Bao, J. Kirkwood, Y. Zakharia +19 more
2021Clinical Trials6 citations
Semantic Scholar
Selection of the recommended phase 2 dose (RP2D) for subcutaneous nemvaleukin alfa: ARTISTRY-2.
O. Hamid, Stephen V. Liu, R. Boccia, Justin Call +16 more
2021Journal of Clinical Oncology6 citations
Semantic Scholar
A phase I, first-in-human trial of KO-947, an ERK1/2 inhibitor, in patients with advanced solid tumors
A. Schram, V. Boni, A. Adjei, A. Olszanski +6 more
2025ESMO Open5 citations Open access
Semantic Scholar
A phase 1/2 study of REGN7075 in combination with cemiplimab (cemi) in patients (pts) with advanced solid tumors: Efficacy and safety results.
N. Segal, E. Girda, D. Sohal, N. Lakhani +15 more
2024Journal of Clinical Oncology5 citations
Semantic Scholar
735 A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors: initial dose-escalation results
M. Johnson, N. Lakhani, E. Girda, A. Olszanski +11 more
2022Regular and Young Investigator Award Abstracts5 citations Open access
Semantic Scholar
Subasumstat, a first-in-class inhibitor of SUMO-activating enzyme, demonstrates dose-dependent target engagement and SUMOylation inhibition, leading to rapid activation of innate and adaptive immune responses in the dose escalation portion of a phase 1/2 clinical study
G. Saggu, D. Stroopinsky, A. Dudek, A. Olszanski +16 more
2022European Journal of Cancer5 citations Open access
Semantic Scholar
Phase I dose escalation of KD033, a PDL1-IL15 bispecific molecule, in advanced solid tumors.
J. Luke, A. Olszanski, I. Puzanov, D. Lu +7 more
20215 citations
Semantic Scholar
598TiP A phase I/Ib dose-escalation study of intravenously administered SB 11285 alone and in combination with nivolumab in patients with advanced solid tumours
J. Luke, F. Janku, J. Strauss, A. Olszanski +3 more
20205 citations Open access
Semantic Scholar
Primary Tumor Characteristics and Next Generation Sequencing Mutations as Biomarkers for Melanoma Immunotherapy Response
Kimberly Loo, G. Gauvin, Iman Soliman, M. Renzetti +7 more
2020Pigment Cell & Melanoma Research5 citations Open access
Semantic Scholar
Melanoma: Cutaneous, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology.
S. Swetter, Douglas B. Johnson, Mark R Albertini, Christopher A. Barker +38 more
2026The Journal of the National Comprehensive Cancer Network4 citations
Semantic Scholar
Phase 1b Study of Tovorafenib, Plozalizumab or Vedolizumab Plus Standard-of-Care Immune Checkpoint Inhibitors in Patients with Advanced Melanoma
R. Sullivan, Katy K. Tsai, A. Pavlick, Elizabeth I. Buchbinder +5 more
2025Journal of Cancer4 citations
Semantic Scholar
SUPRAME: A phase 3 trial comparing IMA203, an engineered T-cell receptor expressing T cell therapy (TCR-T) vs investigator’s choice in patients with previously treated advanced cutaneous melanoma.
J. Luke, Allison Betof Warner, B. Chmielowski, A. Diab +16 more
2025Journal of Clinical Oncology4 citations Open access
Semantic Scholar
Intratumoral INT230-6 (cisplatin, vinblastine, shao) alone or with ipilimumab prolonged survival with favorable safety in adults with refractory sarcomas.
C. Meyer, M. Ingham, James S. Hu, G. Whalen +10 more
2023Journal of Clinical Oncology4 citations
Semantic Scholar
1077TiP TAK-500 as a single agent and in combination with pembrolizumab in patients (pts) with advanced solid tumors: Rationale and design of a phase I/II study
H. Singh, J. Diamond, J. Henry, A. Olszanski +9 more
2023Annals of Oncology4 citations
Semantic Scholar
Conditional dependency of LP-184 on prostaglandin reductase 1 is synthetic lethal in pancreatic cancers with DNA damage repair deficiencies.
Diana Restifo, J. McDermott, D. Cvetkovic, Troy Dos Santos +12 more
2023Molecular Cancer Therapeutics4 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

J. Luke×6
Invite
J. Luke — researcher profile on SciRah
B. Chmielowski×5
Invite
B. Chmielowski — researcher profile on SciRah
J. Farma×5
Invite
J. Farma — researcher profile on SciRah
T. Medina×4
Invite
T. Medina — researcher profile on SciRah

×4

Invite

J. Sosman — researcher profile on SciRah

Invite

S. Swetter — researcher profile on SciRah

G. Karakousis×4

Invite

G. Karakousis — researcher profile on SciRah

Invite

K. Margolin — researcher profile on SciRah

Nicole R. McMillian×4

Invite

Nicole R. McMillian — researcher profile on SciRah

U. Vaishampayan×4

Invite

U. Vaishampayan — researcher profile on SciRah

Invite

D. Juric — researcher profile on SciRah

Invite

Y. Zakharia — researcher profile on SciRah